The use of a darunavir/ritonavir once-daily regimen in two pregnant women

Purpose of the study: Darunavir (DRV) is a second generation protease inhibitor (PI), first licensed for use in 2006. It is indicated for use in a treatment experienced population and is effective in vitro against both wild type and PI-resistant HIV. As a relatively new drug there is little published information on the pharmacokinetics of darunavir in pregnancy. Here we examine the pharmacokinetics of darunavir/ritonavir [DRV/r 800/100mg once daily (OD)] in two women, over the course of pregnancy and postpartum. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P189 Cite this article as: Lambert et al.: The use of a darunavir/ritonavir oncedaily regimen in two pregnant women. Journal of the International AIDS Society 2010 13(Suppl 4):P189. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112970/